Fagron N.V.

Regulatory Filings • Nov 30, 2015

Regulated information Waregem (Belgium)/Rotterdam (Netherlands)¹, 30 November 2015

Fagron responds to press articles of 30 November 2015

On 30 November 2015, certain newspapers published that the takeover discussions on which Fagron has communicated on 2 and 9 October 2015, would have been terminated. Fagron announces today that these discussions have not been terminated, but are protracted, with at this time a limited visibility on a binding offer.

Fagron also refers to its previously communicated update on its outlook for 2015 and the impact thereof on its financing. In this framework, Fagron has commenced discussions with its financing banks and these discussions are currently ongoing. A strengthening of its equity through a public or private capital increase is not excluded in this respect. As soon as one of the aforementioned tracks would materialize or if further developments would take place, Fagron will again report thereon in accordance with its legal obligations.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For further information Constantijn van Rietschoten Chief Marketing Officer / Investor Relations a.i. Tel. +31 6 53 69 15 85 constantijn.van.rietschoten@fagron.com

Fagron profile

Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.